On 1 March 2012, the European Commission published its long-awaited proposal to update Directive 89/105/EEC (the “Transparency Directive”), the key piece of legislation that limits the powers of EU Member States to set prices and reimbursement conditions of medicinal products.
Register Now As you are not an existing subscriber please register for your free daily legal newsfeed service.Register
If you have any questions about the service please contact firstname.lastname@example.org or call Lexology Customer Services on +44 20 7234 0606.
Proposed new EU Transparency Directive on pricing and reimbursement of medicinal products
- Sidley Austin LLP
- Maurits J.F. Lugard, Maarten Meulenbelt, Kristina Nordlander, Scott Bass and James C. Stansel
- European Union
- March 26 2012
To view this article you need a PDF viewer such as Adobe Reader.
If you are interested in submitting an article to Lexology, please contact Andrew Teague at email@example.com.
Director, Legal Services
Cisco Systems, Inc